

15 October 2014



ABN: 56 006 569 106

A: 108 Outram Street
West Perth, WA 6005

T: +61 (8) 9486 2333
F: +61 (8) 9355 4580

Simone Papas
Australian Securities Exchange
Level 4, North Tower Rialto
525 Collins Street
MELBOURNE VIC 3000

REQUEST FOR TRADING HALT

Dear Simone;

Virax Holdings Ltd (ASX Code: VHL) requests a trading halt effective immediately, pending the release of an announcement in relation to a material transaction.

The Company requests the trading halt last from the receipt of this request until the release of the announcement. In any event, no later than the commencement of trading on Friday 17th October 2014.

The Company is not aware of any reason why a trading halt should not be granted.

The Company is not aware of any other information necessary to inform the market about the trading halt.

Yours faithfully,

A blue ink signature of Sean Henbury, written in a cursive style.

Sean Henbury
Company Secretary

About Virax

Virax is a clinical-stage oncology company currently engaged in the development of novel products for the treatment of cancer. It holds an exclusive worldwide license to the novel cancer compound GGTI-2418 for the treatment of multiple myeloma, breast and pancreatic cancer. In addition, the company has granted a licence to major French biotechnology company Transgene for access to its Co-X-Gene™ technology for use in two of Transgene's immunotherapeutic products. These are: TG4001 – a treatment for pathologies relating to human papilloma virus (HPV) infection that can lead to oropharyngeal(head and neck) cancer, and TG4010 – a treatment for non-small cell lung cancer (NSCLC). The board is actively seeking to expand its asset base with complementary technologies and products to maximise shareholder value.